A drug that targets liver scarring from fatty liver disease gained Food and Drug Administration accelerated approval in March, marking the first-ever drug specifically for the disease to get the FDA’s nod. Experts hope the medication, designated a “breakthrough therapy,” proves to be a sign of more treatments to come.
Debra Melani
CU Anschutz
Fitzsimons Building
13001 East 17th Place
Aurora, CO 80045